Material Event Form 8 K

(b)

On January 1, 2025 (the "Dale Separation Date"), Stephen Dale, M.D. tendered his resignation from his position as the Chief Medical Officer of Kura Oncology, Inc. (the "Company"), effective as of January 2, 2025, in order to focus on recovery from personal health challenges.

(e)

On January 1, 2025, in connection with Dr. Dale's resignation, the Company and Dr. Dale entered into a Settlement Agreement (the "Dale Agreement") pursuant to which, among other things, (i) Dr. Dale will be entitled to receive, subject to Dr. Dale's compliance with his obligations under the Dale Agreement, (a) a cash amount equal to 18 months of his base salary in effect as of the Dale Separation Date and (b) Dr. Dale's 2024 annual cash bonus and (ii) the post-termination exercise period during which Dr. Dale may exercise the vested portion of stock options held by him as of the Dale Separation Date will be extended until March 31, 2026, subject to earlier termination as provided in the applicable equity incentive plan and/or stock option agreement.

The foregoing description of the Dale Agreement is not complete and is subject to and qualified in its entirety by reference to the complete text of the Dale Agreement, a copy of which the Company intends to file with the Securities and Exchange Commission as an exhibit to the Company's Annual Report on Form 10-K forthe fiscal year ended December 31, 2024.